Please login to the form below

Not currently logged in
Email:
Password:

Shield Therapeutics’ CFO steps down

Richard Jones to leave the group in early 2017

Richard Jones is to step down from his position as chief financial officer at Shield Therapeutics early next year.

Jones joined the secondary care pharmaceutical specialist in 2010 as a non-executive director before taking on his current role a year later.

He brought nearly 30 years of financial management experience to the firm, with 16 years specialising in the healthcare sector.

Previously, Jones has served as a healthcare consultant for Grant Thornton's healthcare advisory practice, as a strategic advisory board member for Bionow and in a number of senior corporate finance roles specialising in healthcare.

Carl Sterritt, chief executive officer of Shield Therapeutics, said: “Richard has helped build the Group from its inception as a small private company through to being listed on AIM.

“I would like to thank him for his significant contribution to Shield and wish him the best in his future endeavours as we continue to grow rapidly into a commercial-stage specialty pharmaceutical business with international operations."


23rd November 2016

From: Sales

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...